Processa Pharmaceuticals, Inc. (PCSA)

Compare

0.3400

+0.0215

+(6.75%)

At close: April 4 at 4:00:02 PM EDT

0.3010

-0.04

(-11.47%)

After hours: April 4 at 7:59:28 PM EDT

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the MedInvest Biotech and Pharma Investor Conference being held March 27-28, 2025, at Cooley’s law office in New York City. Management will present a corporate overview on Friday, March 28th at 9:40 a.m. Eas

GlobeNewswire 19 days ago

PCSA
+6.75%
Processa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying Recently

We recently published a list of 10 Cheapest Stocks Insiders Are Buying Recently. In this article, we are going to take a look at where Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stands against the other cheap stocks insiders are buying recently. Why should we be interested in affordable stocks? Some investors like to look for cheaper stocks […]

Insider Monkey last month

PCSA
+6.75%
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and safety, today announced its participation in the 2025 BIO CEO & Investor Conference being held February 10-11, 2025, at the New York Marriott Marquis. Management will present a corporate overview on Tuesday, February 11 at 10:00 a.m. Eastern time in the

GlobeNewswire last month

PCSA
+6.75%
Favourable Signals For Processa Pharmaceuticals: Numerous Insiders Acquired Stock

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Simply Wall St. last month

PCSA
+6.75%
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

HANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the closing of its previously announced “reasonable best efforts” public offering with participation from the Company’s Chief Executive Officer, certain board members, and existing institutional investors of the Company, al

GlobeNewswire 2 months ago

PCSA
+6.75%
Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

HANOVER, MD, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced the pricing of its “reasonable best efforts” public offering with participation from the Company’s Chief Executive Officer, certain board members, and existing institutional investors of the Company, along with a heal

GlobeNewswire 2 months ago

PCSA
+6.75%
Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results

First patient dosed in Phase 2 clinical trial with NGC-Cap for metastatic breast cancer Positive data from preclinical studies support NGC-Iri’s ability to deliver more SN-38 to tumors compared with either irinotecan or Onivyde® HANOVER, Md., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, provide

GlobeNewswire 5 months ago

PCSA
+6.75%
Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Phase 2 trial is an adaptive designed randomized study comparing NGC-Cap to monotherapy capecitabineResults from this Phase 2 trial will evaluate NGC-Cap’s safety-efficacy profile and help to define the optimal dosage regimen in patients with metastatic breast cancer HANOVER, Md., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs wit

GlobeNewswire 6 months ago

PCSA
+6.75%
Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences during the month of September: H.C. Wainwright 26th Annual Global Investment Conference, September 9-11, 2024, at the Lotte New York Palace Hotel. Management will be holding one-on-one meetings with investors and will deliver a company presentation. The recorded presentation will be available on demand be

GlobeNewswire 6 months ago

PCSA
+6.75%
Processa Pharmaceuticals Provides Product Pipeline and Financial Update

Phase 2 trial with NGC-Cap in breast cancer underway NGC-Cap Phase 1b trial demonstrated a favorable safety profile with preliminary anti-tumor activity Preclinical studies demonstrated NGC-Iri delivers more cancer-killing SN-38 molecules to tumor than either irinotecan or Onivyde® HANOVER, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherap

GlobeNewswire 7 months ago

PCSA
+6.75%
Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri

Delivers more cancer-killing SN-38 molecules to tumor than irinotecan and Onivyde® Studies support potential benefit as an improved treatment with fewer side effects HANOVER, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces positive data from preclinical studies that support the potential for NGC-Iri to have improved efficacy and a better side effect profile compared with the commonly used FDA-approved cancer treatments irinotecan and Onivyde® (the l

GlobeNewswire 7 months ago

PCSA
+6.75%
Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer

Open-label Phase 2 trial in breast cancer to begin this quarter Initial data expected mid-2025 HANOVER, Md., July 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for Nex

GlobeNewswire 8 months ago

PCSA
+6.75%
Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer

HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the appointment of Russell L. Skibsted as Chief Financial Officer (CFO), effective immediately. Mr. Skibsted succeeds James Stanker, who is retiring and staying on in an advisory role to assist in the transition. “We are delig

GlobeNewswire 8 months ago

PCSA
+6.75%
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses (PR) and one stable disease (SD) For all NGC-Cap doses, 5-Fluorouracil (5-FU) exposure was greater and fluoro-beta-alanine (FBAL) exposure was lower with a better or similar side-effect profile than monotherapy capecitabine HANOVER, MD., June 11, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (

GlobeNewswire 9 months ago

PCSA
+6.75%
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced that management will be participating in the EF Hutton Annual Global Conference being held May 15, 2024 at The Plaza Hotel in New York City. Management will be holding one-on-one meetings with investors. About Process

GlobeNewswire 10 months ago

PCSA
+6.75%
Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced that it has named Steven Cha, M.D. as Senior Vice President of Clinical Research. In this newly created position, Dr. Cha’s experience as an oncolog

GlobeNewswire 11 months ago

PCSA
+6.75%
Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial

NGC-Cap demonstrated greater 5-FU exposure than monotherapy capecitabine at a significantly lower dose with a favorable clinical safety profile NGC-Cap holds potential for improved efficacy in more patients due to an increase in distribution of 5-FU to cancer cells Phase 1b study final results to be released upon database lock HANOVER, Md., April 11, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focus

GlobeNewswire 11 months ago

PCSA
+6.75%
Insider Buyers At Processa Pharmaceuticals Recover Some Losses, But Still Down US$40k

Insiders who bought US$210.6k worth of Processa Pharmaceuticals, Inc. ( NASDAQ:PCSA ) stock in the last year recovered...

Simply Wall St. 11 months ago

PCSA
+6.75%

Performance Overview

Return	PCSA	S&P 500 (^GSPC)
YTD	-61.54%	-13.73%
1-Year	-85.34%	-1.42%
3-Year	-99.45%	+10.72%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Processa Pharmaceuticals, Inc. (PCSA)

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Processa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying Recently

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Favourable Signals For Processa Pharmaceuticals: Numerous Insiders Acquired Stock

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Processa Pharmaceuticals Provides Product Pipeline and Financial Update

Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri

Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer

Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial

Insider Buyers At Processa Pharmaceuticals Recover Some Losses, But Still Down US$40k

Performance Overview